Beta Drugs Limited has informed the Exchange about General Updates
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beta Drugs Limited has revised its valuation report prepared by Mr. Hitesh Jhamb, Registered Valuer, for its proposed preferential issue aimed at acquiring Nivian Life Sciences Private Limited. Earlier, the valuation under the Income Approach and Cost Approach was done using Beta Drugs' standalone financial statements. The report has now been revised to use consolidated financial statements for a more comprehensive view of the company's financial position. The revised Valuation Report dated 08.01.2026 has been uploaded on the company's website. No change in the deal structure or acquisition target has been announced — this is a procedural revision to the supporting valuation.
Shareholders should note that the acquisition of Nivian Life Sciences is progressing, but the valuation methodology has been updated to use consolidated numbers. This is largely a compliance/procedural update and is unlikely to materially affect the deal value or stock price in the short term.